

The following revised determinations on reconsideration, certifying eligibility to apply for TAA, have been issued. The

requirements of Section 222(a)(2)(B) (Shift in Production or Services to a Foreign Country Path or Acquisition of

Articles or Services from a Foreign Country Path) of the Trade Act have been met.

TA-W No.	Subject firm	Location	Impact date
93,702 .....	Koppers Inc. ....	Follansbee, WV .....	5/28/2018
93,702A .....	Koppers Inc. ....	Clairton, PA .....	5/28/2018
94,354 .....	iMedX, Inc. ....	Atlanta, GA .....	7/14/2018

I hereby certify that the aforementioned determinations were issued during the period of *June 1st through June 30th 2019*. These determinations are available on the Department's website [https://www.doleta.gov/tradeact/petitioners/taq\\_search\\_form.cfm](https://www.doleta.gov/tradeact/petitioners/taq_search_form.cfm) under the searchable listing determinations or by calling the Office of Trade Adjustment Assistance toll free at 888-365-6822.

Signed at Washington, DC, this 22nd day of July 2019.

**Hope D. Kinglock,**

*Certifying Officer, Office of Trade Adjustment Assistance.*

[FR Doc. 2019-17700 Filed 8-16-19; 8:45 am]

**BILLING CODE 4510-FN-P**

## NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice: (19-047)]

### Notice of Centennial Challenge Vascular Tissue Challenge

**AGENCY:** National Aeronautics and Space Administration (NASA).

**ACTION:** Notice.

**SUMMARY:** This notice is updating the Centennial Challenge Vascular Tissue Challenge that was published June 13, 2016, Document Number 2016-13795. The Vascular Tissue Challenge is open and teams that wish to compete may now register. Centennial Challenges is a program of prize competitions to stimulate innovation in technologies of interest and value to NASA and the nation. The Vascular Tissue Challenge is a prize competition with a \$500,000 prize purse for teams that can successfully create thick, human vascularized organ tissue in an in vitro environment while maintaining metabolic functionality similar to their in vivo functionality throughout a 30-day survival period. NASA is providing the prize purse. The Methuselah Foundation's New Organ Alliance is the Allied Organization managing the competition.

**DATES:** This is a "first to demonstrate" competition. Teams must submit their intent to compete by September 30th,

2019, and all trials need to be completed by the Trial Deadline of September 30th, 2020.

**ADDRESSES:** The Vascular Tissue Challenge will be conducted and judged at the laboratory facilities of the participants.

**FOR FURTHER INFORMATION CONTACT:** To register for or get additional information regarding the Vascular Tissue Challenge, please visit: <https://www.neworgan.org/prizes/vascular-tissue-prize/>.

For general information on the NASA Centennial Challenges Program please visit: <http://www.nasa.gov/challenges>. General questions and comments regarding the program should be addressed to Monsi Roman, Centennial Challenges Program, NASA Marshall Space Flight Center Huntsville, AL 35812. Email address: [hq-stmd-centennialchallenges@mail.nasa.gov](mailto:hq-stmd-centennialchallenges@mail.nasa.gov).

#### SUPPLEMENTARY INFORMATION:

##### Summary

Competitors will be asked to produce an in vitro vascularized tissue that is >1 centimeter in thickness in all dimensions at the launch of the trial and maintains >85% survival of the required parenchymal cells throughout a 30 calendar day period. Tissues must provide adequate blood perfusion without uncontrolled leakage into the bulk tissue to maintain metabolic functionality similar to their in vivo native cells. Histological measurement of the quality and amount of functional performance will be required to determine survival of parenchymal tissue. Teams must demonstrate 3 successful trials with at least a 75% trial success rate to win an award. In addition to the in-vitro trials, teams must also submit a Spaceflight Experiment Concept that details how they would further advance an aspect of their tissue vascularization research through a microgravity experiment that could be conducted in the U.S. National Laboratory (ISS-NL) onboard the International Space Station.

#### I. Prize Amounts

The total Vascular Tissue Challenge prize purse is \$500,000 (five hundred

thousand U.S. dollars). First place will receive \$300,000 (three hundred thousand U.S. dollars). Two runners-up may be awarded \$100,000 (one hundred thousand U.S. dollars) each. Entries must meet specific requirements detailed in the Rules to be eligible for prize awards.

#### II. Eligibility To Participate and Win Prize Money

To be eligible to win a prize, competitors must:

(1) Register and comply with all requirements in the rules and Team Agreement;

(2) In the case of a private entity, shall be incorporated in and maintain a primary place of business in the United States, and in the case of an individual, whether participating singly or in a group, shall be a citizen or permanent resident of the United States; and

(3) Not be a Federal entity or Federal employee acting within the scope of their employment.

#### III. Official Rules

The complete rules for the Vascular Tissue Challenge can be found at: <https://www.neworgan.org/prizes/vascular-tissue-prize/>.

**Cheryl Parker,**

*NASA Federal Register Liaison Officer.*

[FR Doc. 2019-17789 Filed 8-16-19; 8:45 am]

**BILLING CODE 7510-13-P**

## NUCLEAR REGULATORY COMMISSION

[Docket No. 50-289; NRC-2018-0266]

### Exelon Generation Company, LLC; Three Mile Island Nuclear Station, Unit 1

**AGENCY:** Nuclear Regulatory Commission.

**ACTION:** License amendment application; withdrawal by applicant.

**SUMMARY:** The U.S. Nuclear Regulatory Commission (NRC) has granted the request of Exelon Generation Company, LLC to withdraw its application dated September 20, 2018, for a proposed amendment to Renewed Facility

Operating License No. DPR-50 for the Three Mile Island Nuclear Station, Unit 1. The proposed amendment would have revised Technical Specification 4.4.2.1, "Inservice Tendon Surveillance Requirements," to add the words "except where an alternative, exemption, or relief has been authorized by the NRC" to allow NRC-approved exceptions.

**DATES:** The withdrawal of the proposed amendment takes effect on August 19, 2019.

**ADDRESSES:** Please refer to Docket ID NRC-2018-0266 when contacting the NRC about the availability of information regarding this document. You may obtain publicly-available information related to this document using any of the following methods:

- **Federal Rulemaking Website:** Go to <https://www.regulations.gov> and search for Docket ID NRC-2018-0266. Address questions about NRC docket IDs in *Regulations.gov* to Jennifer Borges; telephone: 301-287-9127; email: [Jennifer.Borges@nrc.gov](mailto:Jennifer.Borges@nrc.gov). For technical questions, contact the individual listed in the **FOR FURTHER INFORMATION CONTACT** section of this document.

- **NRC's Agencywide Documents Access and Management System (ADAMS):** You may obtain publicly-available documents online in the ADAMS Public Documents collection at <https://www.nrc.gov/reading-rm/adams.html>. To begin the search, select "Begin Web-based ADAMS Search." For problems with ADAMS, please contact the NRC's Public Document Room (PDR) reference staff at 1-800-397-4209, 301-415-4737, or by email to [pdr.resource@nrc.gov](mailto:pdr.resource@nrc.gov). The ADAMS accession number for each document referenced (if it is available in ADAMS) is provided the first time that it is mentioned in this document.

- **NRC's PDR:** You may examine and purchase copies of public documents at the NRC's PDR, Room O1-F21, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852.

**FOR FURTHER INFORMATION CONTACT:** Justin C. Poole, U.S. Nuclear Regulatory Commission, Washington DC 20555-0001; telephone: 301-415-2048, email: [Justin.Poole@nrc.gov](mailto:Justin.Poole@nrc.gov).

**SUPPLEMENTARY INFORMATION:**

The NRC has granted the request, dated June 17, 2019 (ADAMS Accession No. ML19169A031), of Exelon Generation Company, LLC (the licensee) to withdraw its application, dated September 20, 2018 (ADAMS Accession No. ML18263A199), for proposed amendment to Renewed Facility Operating License No. DPR-50 for the

Three Mile Island Nuclear Station, Unit 1, located in Dauphin County, Pennsylvania.

The amendment would have revised Technical Specification 4.4.2.1, "Inservice Tendon Surveillance Requirements." The amendment would have added the words "except where an alternative, exemption, or relief has been authorized by the NRC" to allow NRC-approved exceptions to the section 50.55a of title 10 of the *Code of Federal Regulations* requirements. Also, the amendment would have added a note to exempt from the requirements of Surveillance Requirement 4.0.1.

Exelon's September 20, 2018, request was noticed in the **Federal Register** on November 20, 2018 (83 FR 58613).

Dated at Rockville, Maryland, this 13th day of August, 2019.

For the Nuclear Regulatory Commission.

**James G. Danna,**

*Chief, Plant Licensing Branch I, Division of Operating Reactor Licensing, Office of Nuclear Reactor Regulation.*

[FR Doc. 2019-17684 Filed 8-16-19; 8:45 am]

**BILLING CODE 7590-01-P**

## POSTAL SERVICE

### Market Test of Experimental Product: "Plus One"

**AGENCY:** Postal Service™.

**ACTION:** Notice of market test.

**SUMMARY:** The Postal Service gives notice of a market test of an experimental product in accordance with statutory requirements.

**DATES:** August 19, 2019.

**FOR FURTHER INFORMATION CONTACT:** David H. Rubin, 202-268-2986.

**SUPPLEMENTARY INFORMATION:** The United States Postal Service hereby gives notice pursuant to 39 U.S.C. 3641(c)(1) that it plans to begin a market test of its "Plus One" experimental product on October 1, 2019. The Postal Service has filed with the Postal Regulatory Commission a notice setting out the basis for the Postal Service's determination that the market test is covered by 39 U.S.C. 3641, and describing the nature and scope of the market test. Documents are available at [www.prc.gov](http://www.prc.gov), Docket No. MT2019-1.

**Brittany M. Johnson**

*Attorney, Federal Compliance.*

[FR Doc. 2019-17704 Filed 8-16-19; 8:45 am]

**BILLING CODE 7710-12-P**

## RAILROAD RETIREMENT BOARD

### Sunshine Act Meetings

**TIME AND DATE:** 10:00 a.m., August 28, 2019.

**PLACE:** 8th Floor Board Conference Room, 844 North Rush Street, Chicago, Illinois 60611.

**STATUS:** This meeting will be open to the public.

**MATTERS TO BE CONSIDERED:**

- (1) Update from Wisconsin Central Working Group
- (2) Status update on Albany Field Office
- (3) Welcome new Director of Operations/Project Management, Terryne Murphy.

**CONTACT PERSON FOR MORE INFORMATION:**

Stephanie Hillyard, Secretary to the Board, Phone No. 312-751-4920.

Dated: August 15, 2019.

**Stephanie Hillyard,**

*Secretary to the Board.*

[FR Doc. 2019-17913 Filed 8-15-19; 4:15 pm]

**BILLING CODE 7905-01-P**

## SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-86643; File No. SR-NYSEArca-2019-04]

### Self-Regulatory Organizations; NYSE Arca, Inc.; Notice of Designation of a Longer Period for Commission Action on Proceedings To Determine Whether To Approve or Disapprove a Proposed Rule Change Amending NYSE Arca Rule 5.2-E(j)(3) To Adopt Generic Listing Standards for Investment Company Units Based on an Index of Municipal Bond Securities

August 13, 2019.

On February 8, 2019, NYSE Arca, Inc. ("NYSE Arca" or "Exchange") filed with the Securities and Exchange Commission ("Commission"), pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act")<sup>1</sup> and Rule 19b-4 thereunder,<sup>2</sup> a proposed rule change to amend NYSE Arca Rule 5.2-E(j)(3) to adopt generic listing standards for Investment Company Units based on an index or portfolio of municipal securities. The proposed rule change was published for comment in the **Federal Register** on February 27, 2019.<sup>3</sup> On April 9, 2019, pursuant to Section 19(b)(2) of the Act,<sup>4</sup> the Commission

<sup>1</sup> 15 U.S.C. 78s(b)(1).

<sup>2</sup> 17 CFR 240.19b-4.

<sup>3</sup> See Securities Exchange Act Release No. 85170 (Feb. 21, 2019), 84 FR 6451.

<sup>4</sup> 15 U.S.C. 78s(b)(2).